Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Leiomyosarcoma

Leiomyosarcoma Clinical Trial

— TAGGED  

Official title:

TAGGED: A Phase 2 Study Using Low Dose/Metronomic Trabectedin, Gemcitabine, and Dacarbazine as 2nd/3rd/4th Line Therapy for Advanced Leiomyosarcoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04535271
• Other study ID #: SOC-2101
• Status: Recruiting
• Phase: Phase 2
• Start date: September 9, 2021
• Est. completion date: December 30, 2024

Study information

• Verified date: November 2023
• Source: Sarcoma Oncology Research Center, LLC
• Contact: Sant P Chawla, MD
• Phone: 3105529999
• Email: santchawla[@]sarcomaoncology.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open label phase 2 study using metronomic doses of trabectedin, gemcitabine and dacarbazine given intravenously.

Description:

This is an open label phase 2 study using metronomic doses of trabectedin, gemcitabine and dacarbazine given intravenously.

A total of 80 patients will receive trabectedin 0.5 mg/m2 as 24 hour continuous intravenous infusion (CIV) on D1 and D8, gemcitabine 250 mg/m2 i.v. on D1 and D8, and dacarbazine 250 mg/m2 i.v. on D1 and D8 (see product information; www.accessdata.fda.gov). Treatment cycles are given every 3 weeks. Patients in this study may continue treatment until significant disease progression or unacceptable toxicity occurs up to one year of therapy. Patients who withdraw or do not complete the first 2 treatment cycles and first follow up CT scan/MRI will be replaced.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 80
• Est. completion date: December 30, 2024
• Est. primary completion date: September 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male or Female = 18 years of age

• Pathologically confirmed diagnosis of locally advanced, unresectable or metastatic leiomyosarcoma

• Previously treated patient with measurable disease by RECIST v1.1

• ECOG performance status = 2

• Life expectancy of at least 3 months

• Acceptable liver function: Bilirubin < 1.5 times upper limit of normal (ULN; except subjects with Gilbert Syndrome who must have a total bilirubin level < 3.0 ULN); AST (SGOT), ALT (SGPT) and alk phos < 2.5 x ULN (< 5 x ULN if liver metastases present)

• Acceptable renal function: Creatinine < 1.5 times ULN and creatinine clearance > 60 ml/min using the Crockroft-Gault formula

• Acceptable hematologic status: ANC >1000 cells/µL; Platelet count >100,000/µL; Hemoglobin > 9.0 g/dL

• INR and PT < 1.5 ULN unless taking anti-coagulation, in which case PT, INR and aPTT must be within therapeutic range of intended use of anticoagulants

• Ability to understand the purposes and risks of the study and has signed and dated a written informed consent form approved by the Investigator's IRB/Ethics Committee

• Willingness to comply with all study procedures and availability for the duration of the study

• All women of childbearing potential must have a negative urine or serum pregnancy test within 72 hours of enrollment. If urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required; all subjects must agree to use highly effective means of contraception (surgical sterilization or the use of barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel or an IUD) with their partner from entry into the study through 5 months for women and 7 months for men after the last dose.

Exclusion Criteria:

• Currently receiving treatment with another investigational device or drug study, or <14 days since ending treatment with another investigational device or drug study(s).

• Subject has known sensitivity to trabectedin, gemcitabine or dacarbazine.

• Female subject is pregnant or breast-feeding or planning to become pregnant during study treatment and through 3 months after the last dose of trabectedin, gemcitabine or dacarbazine.

• Female subject of childbearing potential who is unwilling to use acceptable method(s) of effective contraception during study treatment and through 3 months after the last dose of trabectedin, gemcitabine or dacarbazine.

• Sexually active subjects and their partners unwilling to use male or female latex condom

Related Conditions & MeSH terms

• Leiomyosarcoma

Intervention

Drug:
• Trabectedin
This is an open label phase 2 study using metronomic doses of trabectedin, gemcitabine and dacarbazine given intravenously.

Locations

Country	Name	City	State
United States	Sant P Chawla	Santa Monica	California

Sponsors (1)

Lead Sponsor	Collaborator
Sarcoma Oncology Research Center, LLC

Country where clinical trial is conducted

United States, 

References & Publications (2)

Maiti R. Metronomic chemotherapy. J Pharmacol Pharmacother. 2014 Jul;5(3):186-92. doi: 10.4103/0976-500X.136098. — View Citation

www.accessdata.fda.gov/drugsatfda_docs (Trabectedin, Gemcitabine, Dacarbazine)

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression free survival	Progression free survival up to disease progression or death from any cause	12 months
Secondary	Overall Response	Best overall response (BOR) and duration of response (DOR) by RECIST v1.1 via CT scan or MRI	6 weeks
Secondary	Adverse Event	Incidence of treatment-related adverse events	12 months